Boehringer Ingelheim’s KRAS and Lupin’s MEK inhibitor compound (LNP3794) – Licensing, development and Commercialization Agreement
Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential... Read More
Boehringer Ingelheim’s ASF COMBAT market launch: East to use Tool in prevention of African swine fever
Boehringer Ingelheim has developed ASF COMBAT (ASF Comprehensive Online Management and Biosecurity Assessment Tool). This tool enables pig producers to evaluate areas... Read More
AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
Posted on17 Dec 2018
TagsAbbVie, Amgen, biosimilar of sandoz, Boehringer Ingelheim, Fresenius Kabi, humira, Merck, Momenta, Mylan, novartis, Novartis’ Sandoz, Samsung Bioepis, sandoz
Comments0
AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting... Read More
Pharma Strategic Deal Insight : Boehringer Ingelheim and Peking University (PKU)
Boehringer Ingelheim and Peking University (PKU), has strategic partnership for jointly advancing early science innovation across a range of areas of high... Read More
New Indication Approval: Boehringer Ingelheim’s asthma drug, Spiriva Respimat
Boehringer Ingelheim has announced that the US Food and Drug Administration (FDA) approved tiotropium Respimat (marketed as Spiriva Respimat) for the long-term,... Read More
Elanco acquires Boehringer Ingelheim Vetmedica’s US feline, canine & rabies vaccines portfolio
Elanco US Inc., a subsidiary of Eli Lilly and Company, has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc’s (BIVI) US feline,... Read More
New Indication Approval: Jardiance received USFDA’s New Cardiovascular Indication approval
Posted on07 Dec 2016
Comments0
The US Food and Drug Administration (FDA) approved a new indication for Jardiance (empagliflozin) tablets to reduce the risk of cardiovascular death... Read More
Boehringer Ingelheim, Lupin signed co-marketing deal for Empagliflozin in Indian market
Posted on14 Oct 2016
Comments0
Boehringer Ingelheim and Lupin have entered into a partnership to co-market Empagliflozin used for treatment of type 2 diabetes in India. Under... Read More
Boehringer Ingelheim, University of Dundee collaboration for newer class of drug development – proteolysis-targeting chimeras (PROTACs)
Boehringer Ingelheim and the University of Dundee will join forces in an exciting collaboration with the aim to develop a novel class... Read More
Sanofi, Boehringer Ingelheim’s asset swap : Why and How?
Sanofi and Boehringer Ingelheim have agreed to a $25.1 billion asset swap, in which Sanofi will trade its Merial animal-health business for... Read More